3-oxopiperazinium derivatives as agonists of nerve growth factor and their use as medicaments
申请人:Institut d'Investigacions
Biomédiques August PI I Sunyer
公开号:EP2289882A1
公开(公告)日:2011-03-02
New 3-oxopiperazinium derivatives agonists of Nerve Growth Factor and it use as medicaments. Neurotrophin binding to its specific receptor Trk A leads to the activation of multiple signalling cascades, culminating in neuroregenerative effects, including neuronal survival and neurite outgrowth. Neurotrophic factors have been used for the treatment of several neurodegenerative diseases. However, their use is limited by their inability to cross the blood-brain barrier, their short half life and their side effects. Small molecule neurotrophin peptidomimetics may be beneficial in treating a number of neurodegenerative disorders. The present invention shows the capacity of nerve growth factor agonist molecules derived from the 3-oxopiperazinium scaffold to induce differentiation in PC12 cells and, therefore, that these small molecules with NGF agonist activity may be beneficial for treatment of neurodegenerative diseases, due to their neuroregenerative effects.
新的3-氧代哌嗪衍生物是神经生长因子的激动剂,用作药物。 神经营养因子与其特异受体Trk A结合,导致多种信号级联的激活,最终产生神经再生效应,包括神经元存活和神经突起生长。 神经营养因子已被用于治疗多种神经退行性疾病。 然而,它们的使用受到限制,因为它们无法穿过血脑屏障,半衰期短,且有副作用。 小分子神经营养因子肽类似物可能有助于治疗多种神经退行性疾病。 本发明显示了从3-氧代哌嗪銨骨架衍生的神经生长因子激动剂分子诱导PC12细胞分化的能力,因此,这些具有NGF激动剂活性的小分子可能有助于治疗神经退行性疾病,由于其神经再生效应。